NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Selumetinib (Primary)
- Indications CNS cancer; Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 13 Sep 2019 Status changed from recruiting to suspended.
- 11 Apr 2018 Planned End Date changed from 30 Apr 2022 to 30 Sep 2024.
- 11 Apr 2018 Planned primary completion date changed from 31 Mar 2022 to 30 Sep 2024.